Chemistry:Besonprodil

From HandWiki
Revision as of 03:20, 6 February 2024 by Steve2012 (talk | contribs) (fix)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Besonprodil
Besonprodil.svg
Clinical data
Other namesCI-1041
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H23FN2O3S
Molar mass402.48 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Besonprodil (CI-1041) is a drug which acts as an NMDA antagonist, selective for the NR2B subunit.[1][2] It is under development as a supplemental medication for Parkinson's disease, and has been shown in animals to be effective in counteracting the dyskinesias associated with long-term treatment with levodopa and related drugs.[3][4][5][6][7]

References

  1. "NR2B containing NMDA receptor dependent windup of single spinal neurons". Neuropharmacology 46 (1): 23–30. January 2004. doi:10.1016/S0028-3908(03)00339-3. PMID 14654094. 
  2. "The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression". Epilepsy Research 59 (1): 1–12. March 2004. doi:10.1016/j.eplepsyres.2003.12.010. PMID 15135162. 
  3. "Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin". Movement Disorders 21 (1): 9–17. January 2006. doi:10.1002/mds.20654. PMID 16127720. 
  4. "Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors". Synapse (New York, N.Y.) 60 (3): 239–50. September 2006. doi:10.1002/syn.20295. PMID 16739115. 
  5. "Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias". Journal of Molecular Neuroscience 38 (2): 128–42. June 2009. doi:10.1007/s12031-008-9137-8. PMID 18704766. 
  6. "Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides". Neuropharmacology 58 (1): 286–96. January 2010. doi:10.1016/j.neuropharm.2009.06.030. PMID 19576910. 
  7. "Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias". Neuroscience 167 (4): 1160–7. June 2010. doi:10.1016/j.neuroscience.2010.03.022. PMID 20303391.